JAK3/TEC kinase inhibitor
Ritlecitinib
Brand names: Litfulo
Adult dose
Dose: 50mg PO OD
Route: PO
Frequency: OD
Clinical pearls
- Severe alopecia areata in adults/adolescents ≥12y per NICE TA958
- Pre-treatment screening: TB, hepatitis, varicella, malignancy
Contraindications
- Active serious infection
- Active malignancy
- Severe hepatic impairment
- Pregnancy
- Hypersensitivity
Side effects
- Infections (incl. herpes zoster, TB reactivation)
- MACE
- Malignancy
- VTE
- Cytopenias
- Hepatotoxicity
- Folliculitis
- Headache
Interactions
- Live vaccines
- Strong CYP3A4 modulators
- Other immunosuppressives
Monitoring
- FBC
- Lipids
- LFTs
- Infections
Reference: BNF; NICE TA958; MHRA JAKi class; SmPC; https://bnf.nice.org.uk/drugs/ritlecitinib/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD